PMID-26404844 – Intranasal Oxytocin Dampens Amygdala Reactivity in PTSD
Koch SBJ, van Zuiden M, Nawijn L, Frijling JL, Veltman DJ, Olff M. "Intranasal Oxytocin Normalizes Amygdala Functional Connectivity in Posttraumatic Stress Disorder," Neuropsychopharmacology, 2016;41(8):2041-2051.
Quick Reference
| Property | Value |
|---|---|
| PMID | 26404844 |
| DOI | 10.1038/npp.2015.299 |
| Year | 2016 |
| Journal | Neuropsychopharmacology |
| Study Type | RCT |
| Evidence Level | II |
| Sample | n=77 (37 PTSD patients + 40 trauma-exposed controls) |
| Peptide(s) Studied | Oxytocin |
Key Findings
- Randomized, double-blind, placebo-controlled study in 37 PTSD patients and 40 trauma-exposed healthy controls
- Intranasal oxytocin 40 IU administered as a single dose
- In PTSD patients: oxytocin dampened amygdala reactivity to fearful faces compared to placebo
- In healthy controls: oxytocin paradoxically enhanced amygdala reactivity
- Oxytocin normalized the hyperactive amygdala response characteristic of PTSD
- Suggests context-dependent and population-dependent effects of oxytocin on threat processing
- Supports oxytocin's anxiolytic potential specifically in individuals with heightened amygdala reactivity
Study Design
Randomized, double-blind, placebo-controlled, between-subjects design. 77 participants (37 with PTSD, 40 trauma-exposed controls without PTSD) received a single dose of intranasal oxytocin 40 IU or placebo. fMRI was performed during an emotional face-matching task presenting fearful, angry, and neutral expressions. Amygdala activation and functional connectivity were the primary neuroimaging outcomes.
Limitations
- Single-dose study; chronic dosing effects unknown
- fMRI activation is a surrogate endpoint; clinical symptom improvement not directly measured
- Opposite effects in PTSD vs controls complicate simple therapeutic application
- Cannot determine optimal dosing schedule or whether anxiolytic effect translates to symptom reduction
- Moderate sample size for subgroup analyses
Clinical Relevance
This study provides neuroimaging evidence that oxytocin can normalize the hyperactive amygdala response in PTSD, supporting its anxiolytic potential in trauma-related anxiety disorders. The finding that effects differ between PTSD patients and healthy controls is clinically important — it suggests oxytocin may be most beneficial in populations with pathologically elevated threat responses. For practitioners, this supports targeted use of intranasal oxytocin in anxiety and PTSD protocols rather than general anxiolytic application.
Related
#research #RCT #evidence-level-II